36 min listen
Facing NASH Therapeutic Skepticism with 89bio's Rohan Palekar
Facing NASH Therapeutic Skepticism with 89bio's Rohan Palekar
ratings:
Length:
53 minutes
Released:
Aug 14, 2023
Format:
Podcast episode
Description
The non-alcoholic steatohepatitis (NASH) therapeutics market has proven to be an 11/10 on the difficulty scale. Despite billions of big biopharma dollars invested in therapeutic development, and a few close calls, no therapeutics has yet reached the finish line. On this episode of the Business of Biotech, 89bio CEO Rohan Palekar gives us the insider's perspective on the the challenges that heave beset the field, from a rigorous FDA approval process to poorly designed clinical trials and a wary investor base. Palekar also expresses optimism in his explanation of how, through a focus on safety, convenience, and cutting-edge testing technology to aid patient recruitment, 89bio is positioning itself to break the tape.Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Released:
Aug 14, 2023
Format:
Podcast episode
Titles in the series (100)
002: The Biopharma Exit Strategy With Dr. Francois Nader by Business Of Biotech